HL-60 nuclear extract

Catalog No: 36072 Format: 200 µg ¥33,000 Buy


200 µg of HL-60 nuclear extract at 7.72 µg/µl.


HL-60 nuclear extract was prepared from a cell culture of the human promyelocytic leukemia HL-60 cell line. The HL-60 cell line was originally derived from tumor tissue obtained from a 36 year old female patient with acute promyelocytic leukemia. HL-60 cells are primarily neutrophilic myelocyte precursors in morphology and can be induced to differentiate into granulocytic, monocytic, macrophage-like and eosinophil phenotypes depending on the compound treatment. These cells require insulin and transferrin for growth. In research, HL-60 cells are most commonly used to study myeloid differentiation, hematopoiesis, and acute promyelocytic leukemia. Historically, this cell line was used as a model system to study the effect of DNA topoisomerase IIα and IIβ on differentiation and apoptosis of cells.

Application Notes

HL-60 nuclear extract is recommended for use in studies related to 1) myeloid differentiation, 2) hematopoiesis, and 3) acute promyelocytic leukemia.

Extract Origin

Human myeloblastic leukemia (leukocytes)

Extract Composition

HL-60 nuclear extract is supplied in Dilution Buffer (20 mM Hepes (pH 7.9), 100 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM PMSF and 0.5 mM DTT).

Quality Control

Extracts have been quality control tested by Western blot and the Electrophoretic Mobility Shift Assay (EMSA).


Figure 1: Monitoring AML-1/Runx1 activation with the TransAM AML-1/Runx1 Kit.
Increasing amounts of nuclear extract from unstimulated HeLa and HL-60 cells are tested for AML-1/Runx1 activation using the TransAM AML-1/Runx1 Kit.


To ensure stability, extracts should be stored at -80°C.

We recommend aliquoting the extracts into single-use fractions and then storing them at -80°C. This eliminates repeated freeze/thaw cycles.


This product is guaranteed for 6 months from date of receipt.

This product is for research use only and is not for use in diagnostic procedures.